personalized therapeutic cancer vaccine

Personalized therapeutic cancer vaccines (PTCVs) are a form of immunotherapy designed to stimulate a patient's immune system to recognize and attack tumor cells by targeting patient-specific neoantigens. These neoantigens arise from somatic mutations unique to an individual's tumor and are identified through next-generation sequencing (NGS) of tumor and healthy tissue. The vaccines can be delivered using various platforms, including synthetic peptides, mRNA, DNA, or viral vectors. In the context of the provided data, CeGaT and Cecava have developed a peptide-based PTCV platform that utilizes a median of 20 neoepitope peptides per patient. This approach has been evaluated in glioblastoma multiforme (GBM) patients, demonstrating safety, immunogenicity (inducing both CD4+ and CD8+ T-cell responses), and potential survival benefits in the setting of individual treatment attempts.

Other names

Personalized neoantigen vaccineIndividualized neoantigen-based immunotherapyIndividualized cancer vaccine